

Jean-Pierre Rabs

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2976806/jean-pierre-rabs-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

2,472
citations

11
h-index

18
g-index

18
ext. papers

2,900
ext. citations

6.2
avg, IF

3.38
L-index

#	Paper	IF	Citations
15	APOE Molecular Spectrum in a French Cohort with Primary Dyslipidemia. <i>International Journal of Molecular Sciences</i> , 2022 , 23, 5792	6.3	0
14	Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis. <i>Medical Science Monitor</i> , 2021 , 27, e928784	3.2	1
13	APOE gene variants in primary dyslipidemia. <i>Atherosclerosis</i> , 2021 , 328, 11-22	3.1	10
12	A Simple RFLP-Based Method for Gene Multiplex Amplification and Determination of Hereditary Hemochromatosis-Causing Mutation C282Y and H63D Variant with Highly Sensitive Determination of Contamination. <i>BioMed Research International</i> , 2020 , 2020, 9396318	3	
11	New Sequencing technologies help revealing unexpected mutations in Autosomal Dominant Hypercholesterolemia. <i>Scientific Reports</i> , 2018 , 8, 1943	4.9	13
10	Usefulness of the genetic risk score to identify phenocopies in families with familial hypercholesterolemia?. <i>European Journal of Human Genetics</i> , 2018 , 26, 570-578	5.3	16
9	Familial hypercholesterolemia: experience from France. <i>Current Opinion in Lipidology</i> , 2018 , 29, 65-71	4.4	16
8	High burden of recurrent cardiovascular events in heterozygous familial hypercholesterolemia: The French Familial Hypercholesterolemia Registry. <i>Atherosclerosis</i> , 2018 , 277, 334-340	3.1	18
7	Proprotein convertase subtilisin / kexin 9 (PCSK9) inhibitors and the future of dyslipidemia therapy: an updated patent review (2011-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016 , 26, 1377-1392	6.8	18
6	Characterization of Autosomal Dominant Hypercholesterolemia Caused by PCSK9 Gain of Function Mutations and Its Specific Treatment With Alirocumab, a PCSK9 Monoclonal Antibody. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 823-31		76
5	Exome sequencing in suspected monogenic dyslipidemias. <i>Circulation: Cardiovascular Genetics</i> , 2015 , 8, 343-50		36
4	Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs. <i>Current Atherosclerosis Reports</i> , 2014 , 16, 439	6	72
3	Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation. <i>Human Mutation</i> , 2013 , 34, 83-7	4.7	84
2	Molecular spectrum of autosomal dominant hypercholesterolemia in France. <i>Human Mutation</i> , 2010 , 31, E1811-24	4.7	86
1	Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. <i>Nature Genetics</i> , 2003 , 34, 154-6	36.3	2025